表紙
市場調查報告書

人巨細胞病毒 65 kDa磷蛋白:開發中產品分析

Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 556450
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
人巨細胞病毒 65 kDa磷蛋白:開發中產品分析 Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 58 Pages
簡介

本報告涵括全球人巨細胞病毒 65 kDa磷蛋白的開發中產品,提供目前開發平台狀況和最新趨勢,後期階段及中止的計劃之資訊,主要企業及他們開發中產品評估等資計。

簡介

  • 調查範圍

人巨細胞病毒 65 kDa磷蛋白 - 概要

人巨細胞病毒 65 kDa磷蛋白 - 治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

人巨細胞病毒 65 kDa磷蛋白 - 治療藥的評估

  • 各給藥途徑
  • 各分子類型

人巨細胞病毒 65 kDa磷蛋白的開發治療藥的企業

藥物簡介

人巨細胞病毒 65 kDa磷蛋白 - 開發暫停中的產品

人巨細胞病毒 65 kDa磷蛋白 - 開發中止的產品

人巨細胞病毒 65 kDa磷蛋白 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2059TDB

Summary

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2019, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter of these genes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 3 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Acute Lymphoblastic Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Liver Transplant Rejection, Medulloblastoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.

Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
  • The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
  • Helocyte Biosciences Inc
  • Hookipa Pharma Inc
  • Immunomic Therapeutics Inc
  • Moderna Therapeutics Inc
  • VBI Vaccines Inc
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
  • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytomegalovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytomegalovirus vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HB-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ITI-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ITI-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mRNA-1443 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Triplex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBI-1901 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
  • Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
  • Nov 21, 2019: Immunomic Therapeutics' Collaborator, University of Florida presents new clinical data from ATTAC-II study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
  • Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
  • Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
  • Oct 01, 2019: Immunomic Therapeutics assumes sponsorship of ATTAC-II IND for ITI-1000, a dendritic cell vaccine in phase 2 for the treatment of GBM
  • Sep 11, 2019: VBI to study cancer vaccine with GSK's adjuvant system
  • Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
  • Jun 10, 2019: HOOKIPA Pharma announces oral presentation of HB-101 CMV Vaccine phase 1 data at the American Transplant Congress
  • Jun 04, 2019: VBI Vaccines reports data from part A of the ongoing phase 1/2a study of VBI-1901 in recurrent glioblastoma (GBM) patients at ASCO 2019
  • Apr 23, 2019: VBI Vaccines provides update on GBM program and announces upcoming conference call
  • Apr 03, 2019: VBI Vaccines announces poster presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop
  • Mar 26, 2019: Triplex meets primary endpoint in Phase 2 clinical trial, reduces rate of Cytomegalovirus (CMV) complications in transplant recipients by 50 percent
  • Feb 07, 2019: VBI Vaccines announces third positive DSMB review in phase 1/2a study of VBI-1901 in recurrent GBM patients
  • Dec 17, 2018: HOOKIPA doses first patient in a phase 2 clinical trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus
  • Oct 24, 2018: VBI Vaccines to present initial data for VBI-1901 in recurrent glioblastoma (GBM) patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Helocyte Biosciences Inc, H2 2019
  • Pipeline by Hookipa Pharma Inc, H2 2019
  • Pipeline by Immunomic Therapeutics Inc, H2 2019
  • Pipeline by Moderna Therapeutics Inc, H2 2019
  • Pipeline by VBI Vaccines Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019